Cantargia - New data support differentiation of nadunolimab

Cantargia has presented new data concerning its IL1RAP-targeting antibody, nadunolimab (CAN04), which demonstrates the drug's ability to reduce levels of tumour-promoting molecules in a pancreatic cancer

Related Keywords

Kostenloser Wertpapierhandel ,Novartis , ,Cantargia ,Data ,Support ,Differentiation ,Adunolimab ,